Clinical trials: Hepatic Metastasis
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
This phase II trial tests how well the combination of celecoxib with durvalaumab and tremellimumab works in treating patients with hepatocellular cancer (liver cancer) that may have spread from where it first started to nearby…
- Conditions
- Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT07174570
- Testing
- Celecoxib, Durvalumab, Tremelimumab
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Emory University
Liver Cancer, Intrahepatic Cholangiocarcinoma
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
- Conditions
- Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
- Trial name
- NCT07223307
- Testing
- MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Stanford University
Colorectal Neoplasms, Neuroendocrine Tumors
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
This is a prospective pilot study designed to document safety and efficacy of liver-directed therapy for colorectal, neuroendocrine, cholangiocarcinoma, melanoma, and breast cancer metastases to the liver using Yttrium-90 glass…
- Conditions
- Colorectal Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Melanoma
- Trial name
- NCT01290536
- Testing
- Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)
- Volunteers
- 42 people
- Sponsor
- Nicholas Fidelman, MD
Melanoma (Skin), Metastatic Cancer
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Histamine dihydrochloride may help interleukin-2 kill more tumor cells by making tumor cells more sensitive to the drug.
- Trial name
- NCT00039234
- Testing
- aldesleukin, histamine dihydrochloride
- Where
- 19 sites in United States, Canada and 2 more
- Sponsor
- Maxim Pharmaceuticals
Colorectal Cancer Liver Metastasis
Prospective Validation of an AI Model for Predicting Liver Metastasis in Colorectal Cancer
This is a prospective, multicenter, observational study designed to validate the predictive accuracy of a pre-developed multimodal deep learning model.
- Trial name
- NCT07392567
- Testing
- Multimodal Deep Learning Prediction Model
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Tongji Hospital
Colorectal Cancer
A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
The multicenter, open-label, single-arm, non-randomized, two-stage Simon's design, phase II study (The CLMO-001 Trial) will evaluate the efficacy and safety of bevacizumab in combination with mFOLFOX-6 (Levofolinic acid…
- Trial name
- NCT01383707
- Testing
- 5-Fluorouracil (5-FU), Bevacizumab, Levofolinic acid
- Where
- 11 sites in Italy
- Volunteers
- 77 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Neuroendocrine Tumor With Liver Metastases
Lenvatinib Plus Chemotherapy for pNET Liver Metastases
This prospective, non-randomized, concurrent parallel-controlled study will evaluate treatment response and resistance mechanisms in patients with pancreatic neuroendocrine tumors with liver metastases (pNET-LM) receiving…
- Trial name
- LEN-pNET (NCT07835893)
- Testing
- Lenvatinib, Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Colorectal Liver Metastases
Folfox-B Study for Patients With Colorectal Liver Metastases
Objective: To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver metastases, with the objective to downstage…
- Trial name
- NCT00508872
- Testing
- 5-Fluorouracil, Bevacizumab, Leucovorin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Cholecystitis, Hepatocellular Carcinoma
Low Dose ICG for Biliary Tract and Tumor Imaging
Near-infrared fluorescence (NIRF) imaging after an intravenous injection of indocyanine green (ICG) allows for the intraoperative identification of liver anatomy.
- Conditions
- Cholecystitis, Hepatocellular Carcinoma, Liver Metastases
- Trial name
- ICG (NCT04942665)
- Testing
- Indocyanine green, PINPOINT Endoscopic Fluorescence
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida
Liver Cancer, Pancreatic Cancer
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
The purpose of this study is to evaluate the safety and impact on survival with treatment with 90-Y glass microspheres in conjunction with leucovorin, 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX) as second-line treatment with…
- Trial name
- NCT01581307
- Testing
- FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin), TheraSpheres
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Colorectal Cancer, Metastatic Cancer
Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00002793
- Testing
- fluorouracil, leucovorin calcium
- Where
- Germany
- Volunteers
- 336 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Liver Metastasis, Colon Cancer
EPA for Metastasis Trial 2
A significant proportion of patients who undergo liver surgery to remove bowel cancer that has spread to the liver (metastases) develop disease recurrence and die from the disease.
- Trial name
- EMT2 (NCT03428477)
- Testing
- Icosapent Ethyl
- Where
- 13 sites in United Kingdom
- Volunteers
- 418 people
- Sponsor
- Mark A Hull, PhD FRCP
Colorectal Neoplasms, Liver Neoplasms
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
The study was terminated early due to low enrollment with only 2 subjects enrolled and treated after being open for enrollment for over a year. Therefore, no meaningful efficacy analyses could be performed.
- Trial name
- NCT00106054
- Testing
- Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Colon Cancer Liver Metastasis, Inflammatory Response
Argipressin's Influence on Blood Loss During Hepatic Resection
Infusion of Argipressin during hepatic resection surgery may reduce blood loss. It may also reduce transfusion requirements, and mitigate the perioperative inflammatory response compared to placebo.
- Conditions
- Colon Cancer Liver Metastasis, Inflammatory Response, Vasopressin Causing Adverse Effects in Therapeutic Use
- Trial name
- ARG-01 (NCT05293041)
- Testing
- Argipressin
- Where
- Sweden
- Volunteers
- 248 people
- Sponsor
- Kristina Svennerholm
Colorectal Cancer Liver Metastases
PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES
Capecitabine, oxaliplatin, irinotecan and bevacizumab as perioperative strategy of borderline and/or high risk resectable colorectal cancer liver metastases
- Trial name
- COI-B (NCT02086656)
- Testing
- capecitabine, oxaliplatin, irinotecan and bevacizumab
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Liver Metastases of Colorectal Cancer
Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes
The purpose of this Phase II single-arm study is to prospectively explore the efficacy of chemotherapy plus EGFR inhibitors in patients with liver metastases from total wild-type colorectal cancer with ctDNA superselective…
- Trial name
- NCT06490913
- Testing
- Capecitabine, oxaliplatin, Cetuximab
- Volunteers
- 33 people
- Sponsor
- Fujian Cancer Hospital
Liver Metastases, Mucinous Adenocarcinoma of the Colon
Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
This phase 0 trial is studying whether 2 weeks of cetuximab and dasatinib will change tumor cells in patients with colorectal cancer and liver metastases that can be removed by surgery.
- Conditions
- Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer
- Trial name
- NCT00835679
- Testing
- cetuximab, dasatinib, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Microdevices have been used to ascertain in vivo drug response, which can lead to improved cancer treatment delivery; however, they have not been evaluated for liver tumors.
- Trial name
- NCT07193862
- Testing
- Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Colorectal Carcinoma, Hepatic Metastasis
Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma
In this randomized multicentric phase II study, patients with colorectal carcinoma with resectable hepatic metastasis will be randomized to treatment with dendritic cells or to observation, following conventional treatment with…
- Trial name
- NCT01348256
- Testing
- Dendritic cells vaccine
- Where
- 2 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Hepatectomy, Cancer, Metastatic
Efficacy and Tolerability of Hemopatch After Hepatic Resection
Previous in vitro and in vivo studies detected the Hemopatch Sealing Hemostat® to be a new versatile, self-adhering hemostatic sealing pad consisting of a polyethylene glycol-coated collagen.
- Conditions
- Hepatectomy, Cancer, Metastatic, Hemostasis
- Trial name
- NCT03323359
- Testing
- Hemopatch, Common Surgical Techniques
- Where
- Italy
- Volunteers
- 98 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS